Business Description

Headquartered in California, Affymax, Inc. (NASDAQ: AFFY) is a biopharmaceutical company that is engaged in developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, “Hematide/peginesatide” has completed Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure.

History:

Affymax, Inc. was incorporated   [more]